

## Special Issue

# Alterations of Epigenetics and MicroRNAs in Cancer and Cancer Stem Cell

### Message from the Guest Editor

For this Special Issue of *Genes*, we welcome the submission of reviews, new methods, commentaries, and original articles covering aspects of altered epigenetic and microRNA regulatory processes in cancer. We hope to put a special emphasis on the implication of such processes in cancer stem cell development and maintenance. Contributions are expected to cover topics within the scope of the journal, including but not limited to genetic factors influencing the cancer epigenome, mechanisms impacting mRNA stability in cancer, key chromatin modifiers aberrantly expressed and/or activated in cancer stem cells, as well as pharmacological and genome editing strategies as novel therapeutic tools targeting cancer stem cells' epigenetic signatures.

---

### Guest Editor

Dr. Yannick D. Benoit

Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada

---

### Deadline for manuscript submissions

closed (20 May 2022)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/103019](https://mdpi.com/si/103019)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))